共 50 条
- [41] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical ProgramJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297Cappuzzo, FredericoReck, MartinPapadimitrakopoulou, VassilikiJotte, RobertWest, HowardMok, TonySandler, AlanMocci, SimonettaColeman, ShelleyAsakawa, TakashiSocinski, Mark
- [42] First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialNATURE MEDICINE, 2025, : 1163 - 1170Shen, LinZhang, YanqiaoLi, ZiyuZhang, XiaotianGao, XiangyuLiu, BoWang, YushengBa, YiLi, NingZhang, RuixingZhang, JingdongChen, YeChen, JianHuang, MingzhuFu, YangLiu, MulinLiu, ZhengZhao, JunLi, WeiWei, JiaLi, ChangzhengXu, NongGuo, ZengqingCao, BangweiLiu, LianNie, PengWan, LixinSheng, LiliLiu, ZhenyangHe, YifuGu, KangshengWu, GuowuWang, WeiboZhang, FutongQiu, WenshengGuo, JunYing, JieerPan, HongmingXu, HuitingYuan, YuanBai, YuansongWang, ZhenghuaXu, JiyeZhao, XuehongLiu, HaoZhang, XizhiDai, WenxiangXu, HongyanLiu, MingXie, Lin
- [43] Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1797 - +Galsky, Matthew D.Mortazavi, AmirMilowsky, Matthew, IGeorge, SabyGupta, SumatiFleming, Mark T.Dang, Long H.Geynisman, Daniel M.Walling, RadhikaAlter, Robert S.Kassar, MohamadWang, JueGupta, ShilpaDavis, NancyPicus, JoelPhilips, GeorgeQuinn, David, IHaines, G. Kenneth, IIIHahn, Noah M.Zhao, QianqianYu, MenggangPal, Sumanta K.
- [44] A multicenter, randomized, double-blind, placebocontrolled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progressANNALS OF ONCOLOGY, 2021, 32 : S1426 - S1427Yang, J.Pan, Y.Ning, F.Lin, L.Hu, X.Ma, S.Yu, Q.Wang, C.Wang, X.Ma, R.Zhang, X.Lin, G.Zhao, J.Chen, Y.Cui, J.Wu, G.Yang, N.Wu, Y-L.
- [45] Vandetanib plus pernetrexed versus pemetrexed as 2nd-line therapy in patients with advanced NSCLC: a randomized, double-blind phase III trial (ZEAL)JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S356 - S357de Boer, Richard H.Arrieta, OscarGottfried, MayaBlackhall, Fiona H.Raats, JohannYang, Chih-HsinLangmuir, PeterMilenkova, TsvetaRead, JessicaVansteenkiste, Johan
- [46] Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancerANNALS OF ONCOLOGY, 2010, 21 (01) : 48 - 54Mavroudis, D.Papakotoulas, P.Ardavanis, A.Syrigos, K.Kakolyris, S.Ziras, N.Kouroussis, C.Malamos, N.Polyzos, A.Christophyllakis, C.Kentepozidis, N.Georgoulias, V.
- [47] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552Di Leo, AngeloGomez, Henry L.Aziz, ZebaZvirbule, ZaneteBines, JoseArbushites, Michael C.Guerrera, Stephanie F.Koehler, MariaOliva, CristinaStein, Steven H.Williams, Lisa S.Dering, JudyFinn, Richard S.Press, Michael F.
- [48] A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wu, LinWu, ZhijunXiao, ZeminMa, ZhongshaWeng, JieChen, YanhuaCao, YongqingCao, PeiguoXiao, MaoliangZhang, HuiDuan, HuaxinWang, QianzhiLi, JiaXu, YanPu, XingxiangLi, Kang
- [49] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY OF GEFITINIB (G) VERSUS PLACEBO (P) IN PATIENTS (PTS) WITH ADVANCED NSCLC, NON-PROGRESSING AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (EORTC 08021-ILCP)ANNALS OF ONCOLOGY, 2010, 21 : 124 - 124Surmont, V. F.Gaafar, R. M.Scagliotti, G. V.van Klaveren, R. J.Papamichael, D.Hasan, B.Torri, V.van Meerbeeck, J. P.
- [50] A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Seigel, David R.Hirsch, Fred R.De Boer, Richard H.Natale, Ronald B.Crawford, JeffreyWeiss, Glen J.Glaspy, John A.Fang, AmyBraun, AdaJain, Rajul K.